Translational Development Acquisition TDAC
NASDAQ TDAC
$10.85 +0.01 (+0.05%)
As of: Aug 21, 2026 · 3:58 PM EDT

Translational Development Acquisition (TDAC) Other Operating Expenses (2023)

Translational Development Acquisition's (TDAC) quarterly Other Operating Expenses came in at $485550.0 in Q4 2023.

Translational Development Acquisition (TDAC) Other Operating Expenses (2023) Analysis & Trends

Translational Development Acquisition (TDAC) has 1 years of Other Operating Expenses data on file, last reported at $485550.0 in Q4 2023.

  • Quarterly Other Operating Expenses changed N/A year-over-year to $485550.0 in Q4 2023, while the trailing twelve-month figure through Mar 2025 was $485550.0 (changed N/A YoY) and the FY2023 annual result came in at $485550.0, changed N/A from the prior year.
  • Other Operating Expenses held at $485550.0 in Q4 2023.
  • In the past five years, Other Operating Expenses ranged from a high of $485550.0 in Q4 2023 to a low of $485550.0 in Q4 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oxley Bridge Acquisition 585.76 Mn 585.76 Mn -
2 Launch Two Acquisition 557.86 Mn 557.86 Mn -
3 Drugs Made In America Acquisition 507.00 Mn 507.00 Mn -
4 Cantor Equity Partners IV 468.00 Mn 468.00 Mn -
5 GP-Act III Acquisition 401.06 Mn 401.06 Mn -
6 Aldel Financial 397.49 Mn 397.49 Mn -
7 Republic Digital Acquisition 389.25 Mn 388.51 Mn -
8 Gores Holdings X 385.06 Mn 384.87 Mn -
9 Agriculture & Natural Solutions Acquisition 377.29 Mn 377.04 Mn -
10 Translational Development Acquisition 182.66 Mn 182.57 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2023 485,550.00